Nicholas P. D’AmatoVaxartSouth San Francisco, California, United States
Disclosure(s): Vaxart Inc.: Stocks/Bonds (Public Company)
594 - A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Single Dose, Dose-ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Orally Administered Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females ≥ 18 years Old and Their Breast-feeding Infants
Saturday, October 19, 20242:15 PM – 2:30 PM US PT
